The phase 1/2 trial of the REGEN-COV (casirivimab and imdevimab) antibody cocktail from Regeneron conducted on 799 individuals shows that the antibody treatment can prevent COVID-19 hospitalization ...
Regeneron Pharmaceuticals said its two-antibody “cocktail” REGN-COV2 met its primary endpoint of significantly reducing viral load and medical visits in ambulatory adults with COVID-19 in a Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results